Single B cell screening platform, also known as single B cell cloning technology, is a microsystem based screening method. This platform conducts isolation, screening and evaluation on the B cells, avoiding the cell fusion and the library construction step. Also, single B cell screening platforms usually integrate high throughput platforms, therefore assays could be carried out in a highly efficient manner.
GenScript has built our own single B cell platform by using Beacon™, a micro-chamber based platform. With dozens years of experience on antibody discovery and cell manipulation, GenScript now provides a one-stop solution on antibody discovery using single B cell screening technology.
INTRINSIC ADVANTAGE for CHALENGING TARGET
By isolating, confining, and interrogating each individual B cells, single B cell screening maximizes the antibody repertoires that we can access, therefore it is inherently superior in preserving the B cell diversity. The effective concentration in the microsystem allows the detection for antibody secretion from a single cell within minutes. This means using the single B cell screening platform, lead clones can be identified in less than 1 day. This platform can also be coupled with sample sources from recovered patients PBMC or express immunization of fully human transgenic mice, allowing you to obtain fully human antibody in 1 month! In Feb. 2020, our single B cell screening platform has shown to be an indispensable tool for identifying several promising leads against the 2019 NCP within 12 hours. See our Case Study
122 bead binder
95 cell binder
35 cross reactive to cyno antigen
82 mapped to a different epitope than a positive control antibody
The flow chart shown the results of one of our case study. 8058 single B cell isolated in one chip, 122 of which are antigen specific binders, and 95 of the binders shows activity of cell surface binding. the binders showing cross reactivity with cyno (35) was collected for single cell sequencing.
Hybridoma platform, antibody library platform and single B cell platform are all powerful tools for antibody discovery. The human naïve library is readily used for screening without the immunization process. However, it depends heavily on the library quality, the panning/screening strategy and execution, so the screening success can be difficult to predict. Meanwhile, the nature of the cloning step in library display technology does not ensure the cognate pairing of VL and VH chain. Hybridoma platform is very well established with a long history of success. However, it requires immortalizing B cells with their species specific fusion partner. This greatly reduces the B cell repertoire and limit the use of this technology by the availability of fusion partners to the species origin of B cells. Meanwhile it is time consuming because of its multiple screening processes. Single B cell screening is dramatically expedited (only 1 day in GenScript), and offers the potential in preserving B cell diversity. These days, more and more big name companies are leaning towards this technology to bring a greater and faster success in antibody discovery. You may see the table below for more information.
Hybridoma | Human Naïve Library | GenScript’s Single B Cell Screening Service | |
---|---|---|---|
Antibody Source | Mice or Human | Human | Mice or Human |
B cell Diversity Conservation | 1/1000—1/2000 | Depends | 1/10—4/10 |
Affinity | High | Relatively Lower | High |
Light & Heavy Chain Pair | Y or N | N | Y |
Potential downstream bottleneck | Humanization | Affinity Maturation(Optional) | Single Cell Sequencing |
Screening Duration | 3 months | 1-2 month | 1day |
Based on the mechanism and process of B cell isolation, there are multiple choices on the market to achieve single B cell screening. But for better using it in antibody drug discovery, accuracy, assay capability and sensitivity are the key issues that we need to consider. Here at GenScript, benefited from the OEP system of Beacon™ with the built-in analytical software, we can achieve the precise control and accurate analysis of each single cell, plus our assay versatility, we can deliver you the desired antibody candidates in 1 day!
Sorting Platform | Throughput | Accuracy | Automation | Sensitivity | Assay Capability | |
---|---|---|---|---|---|---|
Multiple test | Cell based assay | |||||
FACS | Medium | Low | Low | Low | Y | N |
Microdroplets | High | Low | Medium | High | Y | N |
Microengraved micro/nanowells |
Medium | Medium | Low | High | N | N |
Microfluidic Chamber (Beacon™) |
Sufficient | High | High | High | Y | Y |
Throughput: 1 chip
Milestone | Item | Time | |
---|---|---|---|
Material preparation | Protein labelling | ||
Cell validation (FACS) | |||
Immunization | Option 1: Immunization with protein (regular animals) | 8-10 Weeks | |
Option 2: Immunization with protein (Humanized mouse) | 8-14 Weeks | ||
Assay on Single B System: Beacon (1 chip) |
Required | Bead-based IgG | 1-2 Weeks* |
Bead-based antigen specific binding | |||
Optional | Cell based epitope mapping against 1 benchmark | ||
Cell based Ag binding assay | |||
Cell based cross species | |||
Cell-based ligand blocking | |||
Bead-based multiplex capture assay (eg. cross species reactivity, extra antigen binding) | |||
Sequencing | Desirable single B cells (given the selection criteria) will be exported for total cDNA recovery and single cell VH/VL sequencing |
1 Week | |
Recombinant Antibody Production | Ab expression & purification | 1-2 Weeks |
*All assays are finished within 1 day. The rest of time is used for data processing and communication with clients.
Throughput: 2 chips, leading to more binders, especially suitable for challenging targets.
Phase | Item | TAT | |
---|---|---|---|
Material preparation | Protein labelling | ||
Cell validation (FACS) | |||
Immunization | Option 1: Immunization with protein (regular animals) | 8-10 Weeks | |
Option 2: Immunization with protein (Humanized mouse) | 8-14 Weeks | ||
Assay on Single B System: Beacon (2 chips) |
Required | Bead-based IgG | 1-2 Weeks* |
Bead-based antigen specific binding | |||
Optional | Cell based epitope mapping against 1 benchmark | ||
Cell based Ag binding assay | |||
Cell based cross species | |||
Cell-based ligand blocking | |||
Bead-based multiplex capture assay (e.g. cross species reactivity, extra antigen binding) | |||
Sequencing | Desirable single B cells (given the selection criteria) will be exported for total cDNA recovery and single cell VH/VL sequencing | 1 Week | |
Recombinant Antibody Production | Ab expression & purification | 1-2 Weeks |
*All assays are finished within 1 day. The rest of time is used for data processing and communication with clients.
Throughput: 2 chips
Phase | Item | TAT | |
---|---|---|---|
Material preparation | DNA plasmid synthesis | ||
DNA validation & Gene bullet preparation | |||
Protein labelling | |||
Cell validation | |||
Immunization | Option 1: Immunization with DNA (regular animals) | 10-12 weeks | |
Option 2: Immunization with cell (regular animals) | |||
Option 3: Immunization with DNA & cell (regular animals) | |||
Assay on Single B System: Beacon (2 chips) |
Required | Bead-based IgG | 1-2 Weeks* |
Cell based Ag binding | |||
Optional | Cell based epitope mapping against 1 benchmark | ||
Cell based cross species | |||
Cell-based ligand blocking | |||
Sequencing | Desirable single B cells (given the selection criteria) will be exported for total cDNA recovery and single cell VH/VL sequencing | 1 Week | |
Recombinant Antibody Production (Optional) | Ab expression & purification | 1-2 Weeks |
*All assays are finished within 1 day. The rest of time is used for data processing and communication with clients.
Our customer service representatives are available 24 hours a day, Monday through Friday to assist you.